1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
Google Scholar | Crossref | Medline2. Ferlay, J, Colombet, M, Soerjomataram, I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941–1953.
Google Scholar | Crossref | Medline3. Mizrahi, JD, Surana, R, Valle, JW, et al. Pancreatic cancer. Lancet 2020; 395: 2008–2020.
Google Scholar | Crossref | Medline4. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, Version 2. 2021, www.nccn.org/patients
Google Scholar5. Von Hoff, DD, Ervin, T, Arena, FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
Google Scholar | Crossref | Medline | ISI6. Conroy, T, Desseigne, F, Ychou, M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
Google Scholar | Crossref | Medline | ISI7. Pusceddu, S, Ghidini, M, Torchio, M, et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel) 2019; 11: 484.
Google Scholar | Crossref8. Yoo, C, Hwang, JY, Kim, JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101: 1658–1663.
Google Scholar | Crossref | Medline | ISI9. Zaniboni, A, Aitini, E, Barni, S, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012; 69: 1641–1645.
Google Scholar | Crossref | Medline | ISI10. Oettle, H, Riess, H, Stieler, JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423–2429.
Google Scholar | Crossref | Medline | ISI11. Zaanan, A, Trouilloud, I, Markoutsaki, T, et al. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer 2014; 14: 441.
Google Scholar | Crossref | Medline12. Gill, S, Ko, YJ, Cripps, C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016; 34: 3914–3920.
Google Scholar | Crossref | Medline | ISI13. Wang-Gillam, A, Li, CP, Bodoky, G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545–557.
Google Scholar | Crossref | Medline | ISI14. Chung, V, McDonough, S, Philip, PA, et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol 2017; 3: 516–522.
Google Scholar | Crossref | Medline15. Portal, A, Pernot, S, Tougeron, D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 2015; 113: 989–995.
Google Scholar | Crossref | Medline | ISI16. Mita, N, Iwashita, T, Uemura, S, et al. Second-line gemcitabine plus nab-paclitaxel for patients with unresectable advanced pancreatic cancer after first-line FOLFIRINOX failure. J Clin Med 2019; 8: 761.
Google Scholar | Crossref17. Sohal, DPS, Kennedy, EB, Cinar, P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. Epub ahead of print 5 August 2020. DOI: 10.1200/JCO.20.01364.
Google Scholar | Crossref18. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
Google Scholar | Crossref | Medline | ISI19. Rahma, OE, Duffy, A, Liewehr, DJ, et al. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013; 24: 1972–1979.
Google Scholar | Crossref | Medline | ISI20. Lawless, JF . Statistical models and methods for lifetime data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc, 2003.
Google Scholar21. Clopper, CJ, Pearson, ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–413.
Google Scholar | Crossref22. de Jesus, VHF, Camandaroba, MPG, Calsavara, VF, et al. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol 2020; 12: 1758835920905408.
Google Scholar | SAGE Journals23. Zaibet, S, Hautefeuille, V, Auclin, E, et al. PD-6 Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study. Ann Oncol 2020; 31: S213–S214.
Google Scholar | Crossref | Medline24. de, la, Fouchardiere, C, Hammel, P, Launay, S, et al. 1566TiP PRODIGE 65—UCGI 36—GEMPAX: a unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma. Ann Oncol 2020; 31: S954–S955.
Google Scholar | Crossref25. Chae, H, Jeong, H, Cheon, J, et al. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol 2020; 12: 1758835920923424.
Google Scholar | SAGE Journals26. Cho, IR, Kang, H, Jo, JH, et al. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study. World J Gastrointest Oncol 2020; 12: 182–194.
Google Scholar | Crossref | Medline27. Loprinzi, CL, Lacchetti, C, Bleeker, J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020; 38: 3325–3348.
Google Scholar | Crossref | Medline28. Flatters, SJL, Dougherty, PM, Colvin, LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth 2017; 119: 737–749.
Google Scholar | Crossref | Medline29. Staff, NP, Grisold, A, Grisold, W, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 2017; 81: 772–781.
Google Scholar | Crossref | Medline